Loading provider…
Loading provider…
Infectious Disease Physician in Duarte, CA
NPI: 1013925551Primary Employer
City of Hope Medical - San Bernardino Radiation Oncology
cityofhope.org
HQ Phone
Get MD Randy's Phone Numberphone_androidMobile
Get MD Randy's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
OR State Medical License
1998
CA State Medical License
2007 - 2025

American Board of Internal Medicine
Infectious Disease
UCSF School of Medicine
medschool.ucsf.edu
Internship • Internal Medicine
1988 - 1989
Medical School
Until 1988
Tufts Medical Center
Fellowship • Infectious Disease
1993 - 1995
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 34 | 83 |
| 2 | 99223Initial hospital inpatient care, typically 70 minutes per day | 34 | 34 |
| 3 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 27 | 41 |
| 4 | 99222Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 13 | 14 |
Updates in infection risk and management in acute leukemia.
Authors: Divya Koura
Journal: Hematology Am Soc Hematol Educ Program
Authors: Maziarz, Richard T, Sridharan, Praseeda, Slater, Susan, Meyers, Gabrielle, Post, Mary, Erdman, Dean D, Peret, Teresa C-T, Taplitz, Randy A
Journal: Biol Blood Marrow Transplant
Publication Date: 2009-09-23
Authors: Robert El-Kareh, Gregory Seymann, Francesca Torriani, Ian Jenkins, Shira Abeles, Sharon Reed
Journal: Jt Comm J Qual Patient Saf
Publication Date: 2020-05-21
Lead Sponsor: Chimerix
Intervention / Treatment: DRUG: Brincidofovir
Lead Sponsor: GeoVax, Inc.
Intervention / Treatment: DRUG: Placebo Administration, BIOLOGICAL: Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
Lead Sponsor: Chimerix
Intervention / Treatment: DRUG: CMX001